2-aryl propionic acid-L-tryptophan compound as well as preparation method and application thereof

By designing and synthesizing 2-arylpropionate-L-tryptophan compounds, the problems of high toxicity and difficulty in synthesis of existing GRPR small molecule drugs have been solved, effective inhibition and inflammation treatment of GRPR are achieved, and excellent anti-inflammatory treatment has been demonstrated. Effects, with broad therapeutic prospects.

CN118908942AActive Publication Date: 2024-11-08HEFEI UNIV OF TECH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410974206.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08
Estimated Expiration
2044-07-19

AI Technical Summary

Technical Problem

Existing GRPR small molecule drugs have problems such as high toxicity and difficulty in synthesis, which makes it difficult to effectively inhibit GRPR, resulting in limited application in inflammatory treatment.

Method used

Design and synthesize a 2-arylpropionate-L-tryptophan compound, and prepare a novel structure through amide condensation and hydrolysis reaction, which is used to prepare GRPR small molecule inhibitors and treatments related to abnormal expression of GRPR activity disease.

Benefits of technology

The compounds show excellent anti-inflammatory effects and can effectively inhibit cisplatin-induced inflammation of renal tubular epithelial cells in mice, with potential application prospects for the treatment of diseases such as inflammation, neurodegenerative diseases and renal fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908942A_ABST
    Figure CN118908942A_ABST
Patent Text Reader

Abstract

The invention discloses a 2-aryl propionic acid-L-tryptophan compound as well as a preparation method and application thereof, and relates to the technical field of medicinal chemistry, and the 2-aryl propionic acid-L-tryptophan compound with a novel structure is designed and successfully synthesized by utilizing a splicing principle. Meanwhile, the protection effect of the compounds on cisplatin-induced mouse renal tubular epithelial cell inflammation is tested, and the result shows that part of the compounds show excellent anti-inflammatory effects and are expected to be applied to preparation of GRPR small-molecule inhibitors and drugs for preventing and / or treating diseases related to abnormal expression of GRPR activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical chemistry, and in particular to a 2-arylpropionic acid-L-tryptophan compound and a preparation method and application thereof. Background Art

[0002] Gastrin-releasing peptide (GRP) is a neuroendocrine peptide. Gastrin-releasing peptide receptor (GRPR) is a specific receptor for GRP. The interaction between the two can play many important biologically active functions. For example, inhibiting GRPR can reduce the release of inflammatory factors and alleviate inflammatory response. After binding to GRPR in the human body, GRP can regulate gastric acid secretion and promote gastrointestinal motility. It can also regulate the immune system to release a variety of hormones (such as insulin, somatostatin, glucagon) and regulate the growth of normal tissues and tumor tissues.

[0003] Studies have shown that the specific binding of GRP to GRPR can release inflammatory factors and play an important biologically active function in inflammatory diseases. The binding of GRP to GRPR promotes the production of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 (IL-1β). Inhibiting GRPR can reduce the interaction between GRP and GRPR, inhibit the release of inflammatory factors, and thus reduce the inflammatory response.

[0004] GRPR is an effective target for inflammatory treatment, but there are few reports on small molecule drugs that use GRPR as an inflammatory target, and they have disadvantages such as high toxicity and difficulty in synthesis. Therefore, the development of new GRPR small molecule inhibitors has broad application prospects. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide a 2-arylpropionic acid-L-tryptophan compound and its preparation method and use. This type of compound can not only be used to prepare GRPR small molecule inhibitors, but also can be used to prepare drugs for preventing and / or treating diseases related to abnormal expression of GRPR activity.

[0006] The technical problem to be solved by the present invention is achieved by adopting the following technical solutions:

[0007] One of the purposes of the present invention is to provide a 2-arylpropionic acid-L-tryptophan compound, the structural formula of which is shown below:

[0008]

[0009] Wherein, Ar includes one of substituted phenyl, substituted phenyl, naphthyl, substituted naphthyl, and substituted biphenyl.

[0010] The second object of the present invention is to provide a method for preparing the 2-arylpropionic acid-L-tryptophan compound, comprising the following steps:

[0011] (1) 2-Arylpropionic acid and L-tryptophan methyl ester hydrochloride undergo amide condensation reaction to obtain intermediate A;

[0012] (2) Intermediate A undergoes hydrolysis to obtain intermediate B;

[0013] (3) The intermediate B undergoes an amide condensation reaction with N-aminoethylimidazole hydrochloride to obtain the target compound.

[0014] The synthetic route is as follows:

[0015]

[0016] The third object of the present invention is to provide the use of the 2-arylpropionic acid-L-tryptophan compound in the preparation of GRPR small molecule inhibitors.

[0017] The fourth object of the present invention is to provide the use of the 2-arylpropionic acid-L-tryptophan compound in the preparation of a drug for preventing and / or treating diseases associated with abnormal expression of GRPR activity.

[0018] The diseases associated with abnormal expression of GRPR activity include inflammation, neurodegenerative diseases, renal fibrosis, autoimmune diseases, etc.

[0019] The beneficial effect of the present invention is that the present invention utilizes the splicing principle to design and successfully synthesize 2-arylpropionic acid-L-tryptophan compounds with novel structures, and tests the protective effects of these compounds on cisplatin-induced inflammation of mouse renal tubular epithelial cells. The results show that some compounds exhibit excellent anti-inflammatory effects and are expected to be used in the preparation of GRPR small molecule inhibitors and drugs for the prevention and / or treatment of diseases related to abnormal expression of GRPR activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figures 1 to 3 are respectively 1 H NMR, 13 C NMR and TOF-HRMS spectra;

[0021] Figures 4 to 6 are respectively 1 H NMR, 13 C NMR and TOF-HRMS spectra;

[0022] Figures 7 to 9 are respectively 1 H NMR, 13C NMR and TOF-HRMS spectra;

[0023] Fig.10 The results of the cell survival rate experiment of compound RH-1402; among them, Cis and Cis+Compounds group vs NC group: *p<0.05, **p<0.01, ***p<0.005; Cis+Compounds group vs Cis group: #p<0.05, ##p<0.01, ###p<0.005; means±SD (n=3);

[0024] Fig.11 Real-time PCR was used to detect the mRNA expression levels of inflammatory factors. Among them, Cis and Cis+Compounds group vs NC group: *p<0.05, **p<0.01, ***p<0.005; Cis+Compounds group vs Cis group: #p<0.05, ##p<0.01, ###p<0.005; means±SD (n=3). DETAILED DESCRIPTION

[0025] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further described below in conjunction with specific embodiments and diagrams.

[0026] The present invention provides a 2-arylpropionic acid-L-tryptophan compound, the structural formula of which is shown below:

[0027]

[0028] Wherein, Ar includes one of phenyl, substituted phenyl, naphthyl, substituted naphthyl, substituted biphenyl, and substituted carbazole.

[0029] Specifically, the structural formula of the 2-arylpropionic acid-L-tryptophan compound is shown below:

[0030]

[0031] The present invention provides a method for preparing a 2-arylpropionic acid-L-tryptophan compound, comprising the following steps:

[0032] (1) 2-Arylpropionic acid and L-tryptophan methyl ester hydrochloride undergo amide condensation reaction to obtain intermediate A;

[0033] (2) Intermediate A undergoes hydrolysis to obtain intermediate B;

[0034] (3) The intermediate B undergoes an amide condensation reaction with N-aminoethylimidazole hydrochloride to obtain the target compound.

[0035] The synthetic route is as follows:

[0036]

[0037] Furthermore, the amide condensation reaction is carried out in the presence of an acid binding agent, a condensing agent and an activating agent.

[0038] In some specific embodiments, the acid binding agent is selected from at least one of triethylamine, pyridine, N,N-diisopropylethylamine (DIPEA), sodium carbonate, and potassium carbonate.

[0039] In some specific embodiments, the condensing agent is selected from at least one of dicyclohexylcarbodiimide (DCC), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCl), carbonyldiimidazole (CDI), O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), and 1-n-propyl phosphoric anhydride (T3P).

[0040] In some specific embodiments, the activator is selected from at least one of 1-hydroxybenzotriazole (HOBt), N,N-dimethylpyridine (DMAP), 4-pyrrolidinopyridine (4-PPY), and N-hydroxysuccinimide (HOSu).

[0041] Furthermore, the hydrolysis reaction is carried out under alkaline conditions, and the alkaline conditions are provided by at least one of sodium carbonate, potassium carbonate, sodium hydroxide and potassium hydroxide.

[0042] The present invention also provides use of the 2-arylpropionic acid-L-tryptophan compound in preparing a GRPR small molecule inhibitor.

[0043] The present invention also provides use of the 2-arylpropionic acid-L-tryptophan compound in preparing a drug for preventing and / or treating a disease associated with abnormal expression of GRPR activity.

[0044] The diseases associated with abnormal expression of GRPR activity include inflammation, neurodegenerative diseases, renal fibrosis, autoimmune diseases, etc.

[0045] Example 1

[0046] Synthesis of compound 1:

[0047] Step 1: Add 2-p-toluenepropionic acid (1.00 g, 6.09 mmol), L-tryptophan methyl ester hydrochloride (1.71 g, 6.70 mmol), 30 mL of dichloromethane and DIPEA (1.94 g, 15.0 mmol) to a flask, stir until the solid is completely dissolved, adjust the temperature to -5 to 0 ° C, then add EDCI (1.40 g, 7.30 mmol) and HOBT (0.12 g, 0.88 mmol), stir for 30 min, and naturally warm to room temperature for 4 h. The reaction solution is extracted twice with 30 mL of water, extracted with 5% dilute hydrochloric acid, and column chromatography to obtain intermediate A with a yield of 80.0%. 1 H NMR (600 MHz, DMSO-d 6 )δ10.81(d,J=2.3Hz,1H),8.34(d,J=2.6Hz,1H),7.50(dt,J=8.0,0.9Hz,1H),7 .43-7.39(m,1H),7.33(ddt,J=15.3,8.1,0.9Hz,2H),7.17-7.14(m,2H),6.99( ddd,J=7.9,6.9,1.0Hz,1H),6.96-6.92(m,2H),4.22(t,J=6.6Hz,1H),3.58(s, 3H),3.10-3.07(m,1H),3.07-2.99(m,2H),2.26(s,3H),1.29(d,J=7.1Hz,3H).

[0048] Step 2: Add intermediate A (1.00 g, 2.74 mmol), 30 mL of methanol, 10 mL of water and anhydrous sodium carbonate (1.00 g, 9.40 mmol) to a flask and heat to 55-60°C for 3 h. The reaction solution was adjusted to pH 1-2 with 5% dilute hydrochloric acid, the solid precipitated, filtered, the filter cake was washed with water and dried to obtain intermediate B with a yield of 81.0%. 1 H NMR (600 MHz, DMSO-d 6)δ12.07(s,1H),10.84(d,J=2.2Hz,1H),8.16(d,J=8.0Hz,1H),7.72(dd,J=5.7,3.3Hz,1H),7. 66(dd,J=5.7,3.3Hz,1H),7.54(dd,J=7.9,1.1Hz,1H),7.33(dt,J=8.1,0.9Hz,1H),7.17-7.14 (m,2H),7.09(d,J=2.3Hz,1H),7.05(d,J=3.4Hz,1H),6.97(ddd,J=8.0,6.9,1.0Hz,1H),4.22( s,1H),3.62(q,J=7.0Hz,2H),3.02(dd,J=14.5,8.4Hz,1H),2.24(s,3H),1.17(d,J=7.1Hz,3H).

[0049] Step 3: Add intermediate B (1.00 g, 2.85 mmol), N-aminoethylimidazole hydrochloride (0.46 g, 3.14 mmol), 20 mL of dichloromethane, DIPEA (0.88 g, 6.85 mmol), EDCI (0.66 g, 3.42 mmol) and HOBT (0.06 g, 0.45 mmol) to a flask and stir for 4 h. The reaction solution was filtered to obtain a crude product. The crude product was recrystallized from methanol-water, filtered, the filter cake was washed with water, and dried to obtain the target compound. The yield was 55%; 1 H NMR (600 MHz, DMSO-d 6 )δ10.73(d,J=2.4Hz,1H),8.15(t,J=5.6Hz,1H),8.04(d,J=7.9Hz,1H),7.52–7.46(m,2H),7.29(dt,J=8. 1,0.9Hz,1H),7.06–7.02(m,4H),7.02–6.99(m,2H),6.92(ddd,J=7.9,6.9,1.0Hz,1H),6.89(d,J=2.3Hz,1 H),6.84(t,J=1.1Hz,1H),4.38(td,J=8.2,5.6Hz,1H),3.96–3.90(m,2H),3.64(q,J=7.2Hz,2H),3.33–3. 26(m,1H),2.94(dd,J=14.5,5.6Hz,1H),2.82(dd,J=14.6,8.5Hz,1H),2.24(s,3H),1.26(d,J=7.1Hz,3H). 13 C NMR (151 MHz, DMSO-d 6)δ173.35,171.99,138.90,137.37,136.01,135.28,128.67,128.30,127.21,127.07,123.56,120 .83,119.59,118.44,118.18,111.23,109.88,53.63,45.21,44.09,39.98,27.77,20.68,18.08.C 26 H 29 N 5 O 2 ,HRMS:m / z 444.2391[M+H] + (Calcd.444.2394).

[0050] Example 2

[0051] Synthesis of compound 2:

[0052] The synthesis steps are the same as those of compound 1, except that 2-phenylpropionic acid is used instead of 2-p-toluenepropionic acid. The yield is 55%; 1 H NMR (600 MHz, DMSO-d 6 )δ10.74(d,J=2.1Hz,1H),8.20(t,J=5.5Hz,1H),8.15(d,J=8.1Hz,1H),7.56(s,1H),7.51(d,J=7.8Hz,1H),7.3 0(d,J=8.1Hz,1H),7.24–7.19(m,2H),7.19–7.15(m,3H),7.08(s,1H),7.03(t,J=7.5Hz,1H),6.93(t,J=7.4Hz,1 H),6.91–6.86(m,2H),4.41(td,J=8.3,5.5Hz,1H),4.01–3.91(m,2H),3.71(q,J=7.2Hz,1H),3.38(dq,J=12.4,6 .1Hz,1H),3.34–3.28(m,1H),2.96(dd,J=14.5,5.4Hz,1H),2.84(dd,J=14.5,8.7Hz,1H),1.30(d,J=7.0Hz,3H). 13 C NMR (151 MHz, DMSO-d 6)δ173.19,172.01,141.91,137.33,136.00,128.14,128.10,127.40,127.21,126.36,123.56, 120.83,119.69,118.43,118.18,111.24,109.87,53.65,45.32,44.47,27.77,18.80,18.02.C 25 H 27 N 5 O 2 ,HRMS:m / z 430.2230[M+H] + (Calcd.430.2238).

[0053] Example 3

[0054] Synthesis of compound 3:

[0055] The synthesis steps are the same as those of compound 1, except that (S)-(+)-2-phenylpropionic acid is used instead of 2-p-toluenepropionic acid. The yield is 41%; 1 H NMR (600 MHz, DMSO-d 6 )δ10.78(d,J=2.4Hz,1H),8.32(s,1H),8.28(d,J=7.1Hz,1H),7.51(d,J=7.9Hz,1H),7.38(d,J=1.6Hz,1H),7 .30(d,J=8.1Hz,1H),7.28–7.25(m,4H),7.23–7.19(m,2H),7.17–7.15(m,2H),6.93(t,J=7.3Hz,1H),6.90(d, J=2.4Hz,1H),4.35(td,J=8.4,5.4Hz,1H),4.10(q,J=6.1Hz,2H),3.73–3.68(m,1H),3.42(t,J=6.3Hz,1H),3. 36(dd,J=12.1,5.9Hz,1H),2.97(dd,J=14.5,5.2Hz,1H),2.85(dd,J=14.6,8.9Hz,1H),1.29(d,J=7.0Hz,3H). 13 C NMR (151 MHz, DMSO-d 6)δ173.34,172.22,141.86,136.39,136.01,128.16,128.11,127.44,127.21,126.38,123.61, 121.08,120.84,118.40,118.20,111.29,109.87,53.87,46.81,44.46,27.69,18.77,17.97.C 25 H 27 N 5 O 2 ,HRMS:m / z430.2236[M+H] + (Calcd.430.2238).

[0056] Example 4

[0057] Synthesis of compound 4:

[0058] The synthesis steps are the same as those of compound 1, except that (R)-(-)-2-phenylpropionic acid is used instead of 2-p-toluenepropionic acid. The yield is 42%; 1 H NMR (600 MHz, DMSO-d 6 )δ10.76(s,1H),8.26(d,J=7.2Hz,1H),8.21(s,1H),7.60(d,J=7.9Hz,1H),7.50(d,J=7.9Hz,1H),7.33(d,J=7.6 Hz,1H),7.29(d,J=8.1Hz,1H),7.27–7.26(m,2H),7.22–7.19(m,2H),7.18–7.14(m,3H),6.93(t,J=7.4Hz,1H),6. 89(d,J=2.3Hz,1H),4.35(dt,J=8.4,4.2Hz,1H),4.10–4.06(m,2H),3.71(d,J=7.1Hz,1H),3.40(d,J=5.1Hz,1H) ,3.34(dd,J=14.8,5.8Hz,1H),2.96(dd,J=14.5,5.3Hz,1H),2.84(dd,J=14.6,8.9Hz,1H),1.29(d,J=7.0Hz,3H). 13 C NMR (151 MHz, DMSO-d 6)δ173.33,172.22,141.85,136.32,136.00,128.15,128.10,127.42,127.20,126.37,123.60, 121.15,120.83,118.39,118.19,111.27,109.86,53.87,46.90,44.45,27.67,18.76,17.96.C 25 H 27 N 5 O 2 ,RMS:m / z 430.2233[M+H] + (Calcd.430.2238).

[0059] Example 5

[0060] Synthesis of compound 5:

[0061] The synthesis steps are the same as those of compound 1, except that 2-(4-nitrophenyl)propionic acid is used instead of 2-p-toluenepropionic acid. The yield is 30%; 1 H NMR (600 MHz, DMSO-d 6 )δ10.70(d,J=2.5Hz,1H),8.36(d,J=8.1Hz,1H),8.29(t,J=5.7Hz,1H),8.04–7.96(m,2H),7.74(s,1H),7.49(d,J=7 .9Hz,1H),7.35–7.29(m,2H),7.25(d,J=8.1Hz,1H),7.18(s,1H),7.03–6.96(m,2H),6.90(ddd,J=8.0,6.9,1.0Hz,1H ),6.87(d,J=2.3Hz,1H),4.44(ddd,J=9.6,8.2,5.0Hz,1H),4.07–3.98(m,2H),3.86(q,J=7.1Hz,1H),3.42(dq,J=12 .3,5.8Hz,1H),3.39–3.34(m,1H),2.97(dd,J=14.6,4.9Hz,1H),2.81(dd,J=14.6,9.6Hz,1H),1.31(d,J=7.0Hz,3H). 13 C NMR (151 MHz, DMSO-d 6)δ171.98,149.68,146.08,135.97,128.76,128.28,127.09,123.56,123.33,123.18, 120.77,118.40,118.13,111.16,109.78,53.56,45.65,44.42,27.85,18.54,17.75.C 25 H 26 N 6 O 4 ,HRMS:m / z 475.2086[M+H] + (Calcd.475.2088).

[0062] Example 6

[0063] Synthesis of compound 6:

[0064] The synthesis steps are the same as those of compound 1, except that 2-(3-chlorophenyl)propionic acid is used instead of 2-p-toluenepropionic acid. The yield is 35%; 1 H NMR (600 MHz, DMSO-d 6 )δ10.75(d,J=2.4Hz,1H),8.31(dd,J=8.1,2.4Hz,1H),8.28–8.23(m,1H),7.86(s,1H),7.50(d,J=7. 9Hz,1H),7.31–7.26(m,2H),7.23(d,J=6.4Hz,2H),7.21(d,J=8.2Hz,1H),7.11–7.08(m,1H),7.04–7. 01(m,2H),6.94–6.90(m,2H),4.38(td,J=8.3,5.4Hz,1H),4.04–3.99(m,2H),3.74(q,J=7.3Hz,1H), 3.43–3.33(m,2H),2.97(dd,J=14.5,5.4Hz,1H),2.84(dd,J=14.5,8.7Hz,1H),1.29(d,J=7.0Hz,3H). 13 CNMR (151MHz, DMSO-d 6 )δ172.67,171.98,144.35,136.94,136.00,132.78,129.94,127.32,127.11,126.42,125.98,123 .48,120.83,120.23,118.38,118.17,111.28,109.86,53.81,45.91,44.16,27.78,18.63,17.96.C 25 H26 C1N 5 O 2 ,HRMS:m / z 464.1849[M+H] + (Calcd.464.1848).

[0065] Example 7

[0066] Synthesis of compound 7:

[0067] The synthesis steps are the same as those of compound 1, except that 2-(4-methyl-3-nitrophenyl)propionic acid is used instead of 2-p-toluenepropionic acid. The yield is 30%; 1 H NMR (600 MHz, DMSO-d 6 )δ10.69(d,J=2.5Hz,1H),8.35(dd,J=8.0,1.5Hz,1H),8.28(t,J=5.7Hz,1H),8.00(s,1H),7.83(d,J=1.8 Hz,1H),7.47(d,J=7.9Hz,1H),7.33(dd,J=7.9,2.0Hz,1H),7.30–7.23(m,3H),7.11(s,1H),7.02–6.98(m ,1H),6.91–6.86(m,2H),4.39(td,J=8.4,5.3Hz,1H),4.08–4.02(m,2H),3.81(q,J=7.0Hz,2H),3.42–3.3 8(m,1H),2.97(dd,J=14.5,5.3Hz,1H),2.82(dd,J=14.5,8.9Hz,1H),2.47(s,3H),1.30(d,J=7.0Hz,3H). 13 C NMR (151 MHz, DMSO-d 6 )δ172.46,171.96,148.49,141.42,136.76,135.96,132.58,132.25,130.93,127.10,125.50,123.46,122 .84,120.76,120.46,118.33,118.10,111.21,109.80,53.78,46.17,43.65,39.57,27.79,19.38,17.99.C 26 H 28 N 6 O 4 ,HRMS:m / z 489.1360[M+H] + (Calcd.489.2245).

[0068] Example 8

[0069] Synthesis of compound 8:

[0070] The synthesis steps are the same as those of compound 1, except that 2-(4-methyl-3,5-dinitrophenyl)propionic acid is used instead of 2-p-toluenepropionic acid. The yield is 50%; 1 H NMR (600 MHz, DMSO-d 6 )δ10.60(d,J=2.5Hz,1H),8.44(d,J=8.2Hz,1H),8.30(t,J=5.6Hz,1H),8.00(s,2H),7.52(s,1H ),7.47–7.42(m,1H),7.21(d,J=8.1Hz,1H),7.07(s,1H),6.98–6.95(m,1H),6.89–6.82(m,3H), 4.46(td,J=8.5,5.1Hz,1H),3.98(tt,J=12.3,6.1Hz,2H),3.94–3.84(m,2H),3.36–3.30(m,1H) ,2.96(dd,J=14.5,5.3Hz,1H),2.80(dd,J=14.5,9.0Hz,1H),2.43(s,3H),1.32(d,J=7.0Hz,3H). 13 CNMR (151MHz, DMSO-d 6 )δ171.77,171.52,150.62,142.73,137.42,135.92,128.35,127.11,126.66,124.56,123.44,120 .74,119.62,118.32,118.05,111.18,109.75,53.69,45.24,43.62,39.99,28.02,18.13,14.41.C 26 H 27 N 7 O 6 ,HRMS:m / z534.2094[M+H] + (Calcd.534.2096).

[0071] Example 9

[0072] Synthesis of compound 9:

[0073] The synthesis steps are the same as those of compound 1, except that 2-(4-isobutylphenyl)propionic acid) is used instead of 2-p-toluenepropionic acid. The yield is 50%; 1 H NMR (600 MHz, DMSO-d 6)δ10.74(d,J=2.5Hz,1H),8.16(t,J=5.5Hz,1H),8.06(d,J=8.0Hz,1H),7.52–7.47(m,2H),7.28(d,J=8.1Hz,1H),7.06 (d,J=8.2Hz,3H),7.03–7.00(m,1H),6.99(s,1H),6.98(s,1H),6.95–6.90(m,2H),6.84(d,J=1.1Hz,1H),4.40(d,J=5.7 Hz,1H),3.96–3.90(m,2H),3.66(d,J=7.1Hz,1H),3.36–3.32(m,1H),3.30(d,J=5.7Hz,1H),2.95(dd,J=14.5,5.6Hz,1H ),2.83(dd,J=14.5,8.5Hz,1H),2.37(d,J=7.2Hz,2H),1.84–1.69(m,1H),1.27(d,J=7.1Hz,3H),0.83(d,J=6.6Hz,6H). 13 C NMR (151 MHz, DMSO-d 6 )δ173.35,171.98,139.11,139.03,137.36,136.03,128.65,128.29,127.20,126.92,123.63,120.80,11 9.58,118.45,118.16,111.23,109.86,53.63,45.21,44.31,44.09,39.98,29.63,27.80,22.25,17.98.C 29 H 35 N 5 O 2 ,HRMS:m / z 486.2858[M+H] + (Calcd.486.2864).

[0074] Example 10

[0075] Synthesis of compound 10:

[0076] The synthesis steps are the same as those of compound 1, except that (S)-(+)-2-(4-isobutylphenyl)propionic acid) is used instead of 2-p-toluenepropionic acid. The yield is 50%; 1 H NMR (600 MHz, DMSO-d 6)δ10.74(d,J=2.4Hz,1H),8.15(d,J=5.2Hz,1H),8.06(d,J=8.0Hz,1H),7.52–7.48(m,2H),7.29(d,J=8.1Hz,1H),7.07(s, 1H),7.05(d,J=2.5Hz,2H),6.99(s,1H),6.98(d,J=4.2Hz,2H),6.94–6.92(m,2H),6.84(d,J=1.1Hz,1H),4.40(td,J=8.2, 5.7Hz,1H),3.97–3.91(m,2H),3.67–3.63(m,1H),3.30(dd,J=6.0,3.8Hz,1H),3.27–3.22(m,1H),2.95(dd,J=14.6,5.6Hz ,1H),2.84(dd,J=14.5,8.5Hz,1H),2.37(d,J=7.1Hz,2H),1.79–1.76(m,1H),1.28(d,J=7.1Hz,3H),0.83(d,J=3.0Hz,6H). 13 C NMR (151 MHz, DMSO-d 6 )δ173.35,171.98,139.11,139.03,137.35,136.02,128.65,128.28,127.20,126.92,123.62,120.80,11 9.57,118.44,118.16,111.22,109.86,53.63,45.21,44.27,44.09,39.97,29.64,27.79,22.25,17.98.C 29 H 35 N 5 O 2 ,HRMS:m / z486.2858[M+H] + (Calcd.486.2864).

[0077] Embodiment 11

[0078] Synthesis of compound 11:

[0079] The synthesis steps are the same as those of compound 1, except that loxoprofen is used instead of 2-p-toluenepropionic acid. The yield is 55%; 1 H NMR (600 MHz, DMSO-d 6)δ10.74(s,1H),8.17(t,J=5.8Hz,1H),8.07(dd,J=8.1,3.0Hz,1H),7.50(d,J=8.0Hz,2H),7.31–7.27(m,1H),7.19–7.15(m,1H),7.07(d,J=8.0 Hz,4H),7.03–7.01(m,2H),6.92(t,J=2.6Hz,1H),6.85(s,1H),4.45–4. 36(m,1H),3.95(dq,J=9.3,6.4,5.8Hz,2H),3.88(t,J=6.1Hz,1H),3.68 –3.64(m,1H),2.94(q,J=3.5,3.0Hz,1H),2.93–2.91(m,1H),2.84(dd,J=14.5,8.6Hz,1H),2.43–2.30(m,3H),2.26–2.19(m,1H),2.07(ddd,J=1 8.8,10.4,8.6Hz,1H),1.85(tdt,J=12.1,6.3,3.2Hz,2H),1.70–1.63(m,1H),1.44(dddd,J=12.4,10.7,6.8,3.9Hz,1H),1.28(d,J=7.0Hz,3H). 13 CNMR (151MHz, DMSO-d 6 )δ219.31,173.29,172.01,139.45,137.38,136.03,128.49,128.43,128.30,127.32,127.13,123.58,120.81,119. 60,118.45,118.17,111.29,110.13,53.61,50.05,45.22,44.09,39.98,37.62,34.57,28.73,20.06,18.78,17.94.C 31 H 35 N 5 O 3 ,HRMS:m / z526.2811[M+H] + (Calcd.526.2813).

[0080] Example 12

[0081] Synthesis of compound 12:

[0082] The synthesis steps are the same as compound 1, except that ketoprofen is used instead of 2-p-toluenepropionic acid. The yield is 33%; 1 H NMR (600 MHz, DMSO-d 6)δ10.67(d,J=2.4Hz,1H),8.29(d,J=8.0Hz,1H),8.20(t,J=5.6Hz,1H),7.69–7.65(m,4H),7.57(dt,J=7.6,1.6H z,1H),7.53–7.46(m,5H),7.42(t,J=7.6Hz,1H),7.26(d,J=8.0Hz,1H),7.08–7.03(m,1H),7.00(ddd,J=8.1,6.9, 1.2Hz,1H),6.92–6.88(m,1H),6.85(d,J=2.4Hz,2H),4.42(td,J=8.2,5.7Hz,1H),4.00–3.88(m,2H),3.83(d,J= 7.1Hz,1H),3.35–3.27(m,2H),2.96(dd,J=14.5,5.6Hz,1H),2.83(dd,J=14.6,8.4Hz,1H),1.33(d,J=7.0Hz,3H). 13 C NMR (151 MHz, DMSO-d 6 )δ195.81,172.80,171.86,142.49,137.09,136.78,135.97,132.64,131.76,129.66,128.61,128.54,128.42,128.07,127 .18,123.57,123.38,120.82,118.57,118.39,118.17,111.25,110.10,109.90,53.69,45.21,44.33,39.97,27.87,18.28.C 32 H 31 N 5 O 3 ,HRMS:m / z 534.2493[M+H] + (Calcd.534.2500).

[0083] Embodiment 13

[0084] Synthesis of compound 13:

[0085] The synthesis steps are the same as those of compound 1, except that naproxen is used instead of 2-p-toluenepropionic acid. The yield is 50%; 1 HNMR (600 MHz, DMSO-d 6)δ10.84(d,J=2.4Hz,1H),8.24(d,J=8.3Hz,1H),8.13(s,1H),7.72(dd,J=16.4,8.8Hz,2H),7.69–7.66(m,1H),7.62(dd,J=7.9,1.1Hz, 1H),7.44(d,J=1.1Hz,1H),7.41(dd,J=8.5,1.8Hz,1H),7.36–7.31(m,1H),7.25(d,J=2.5Hz,1H),7.12(dd,J=8.8,2.5Hz,2H),7.07(d,J =1.2Hz,1H),6.99(t,J=1.0Hz,1H),6.94(t,J=1.2Hz,1H),6.74(t,J=1.1Hz,1H),4.50(td,J=8.4,5.7Hz,1H),3.87–3.79(m,6H),3.28( dq,J=12.6,6.0Hz,1H),3.22(dq,J=13.6,5.6Hz,1H),3.03(dd,J=14.4,5.6Hz,1H),2.92(dd,J=14.5,8.6Hz,1H),1.27(d,J=7.0Hz,3H). 13 C NMR (151 MHz, DMSO-d 6 )δ173.23,171.84,156.97,137.30,137.28,136.08,133.11,129.12,128.36,128.26,127.41,126.69,126.51,125.40, 123.59,120.90,119.51,118.59,118.54,118.23,111.32,110.18,105.67,55.15,53.55,45.13,44.59,28.14,18.74.C 30 H 31 N 5 O 3 ,HRMS:m / z 510.2495[M+H] + (Calcd.510.2500).

[0086] Embodiment 14

[0087] Synthesis of compound 14:

[0088] The synthesis steps are the same as those of compound 1, except that flurbiprofen is used instead of 2-p-toluenepropionic acid. The yield is 55%; 1 H NMR (600 MHz, DMSO-d 6)δ10.85(d,J=2.5Hz,1H),8.33(d,J=8.2Hz,1H),8.22(t,J=5.7Hz,1H),7.63(d,J=7.9Hz,1H),7.53–7.50(m,2H),7.47–7.46(m,2H),7 .44(d,J=3.9Hz,1H),7.42(d,J=8.2Hz,1H),7.39(d,J=7.0Hz,1H),7.34(d,J=8.0Hz,1H),7.24–7.17(m,2H),7.12(d,J=2.4Hz,1H),7.0 8–7.05(m,1H),7.00(d,J=7.5Hz,1H),6.98(d,J=2.7Hz,1H),6.79(s,1H),4.55–4.47(m,1H),3.90(td,J=5.9,2.7Hz,2H),3.78(t,J=7 .2Hz,1H),3.35–3.32(m,1H),3.28(d,J=5.6Hz,1H),3.04(dd,J=14.4,5.7Hz,1H),2.93(dd,J=14.5,8.6Hz,1H),1.22(d,J=7.0Hz,3H). 13 C NMR (151 MHz, DMSO-d 6 )δ172.56,171.77,158.78(d,J=245.3Hz),144.09(d,J=7.7Hz),137.29,136 .07,135.05,130.37(d,J=3.6Hz),128.72(d,J=2.8Hz),128.61,128.26,127 .72,127.38,123.96(d,J=2.9Hz),123.58,120.89,119.51,118.57,118.22, 115.03,114.88,111.31,110.10,53.58,45.17,44.08,28.16,18.57,17.85.C 31 H 30 FN 5 O 2 ,HRMS:m / z 524.2449[M+H] + (Calcd.524.2456).

[0089] Embodiment 15

[0090] Synthesis of compound 15:

[0091] The synthesis steps are the same as those of compound 1, except that carprofen is used instead of 2-p-toluenepropionic acid. The yield is 56%; 1HNMR (600 MHz, DMSO-d 6 )δ11.41(s,1H),10.78(s,1H),8.28–8.22(m,2H),8.15(dd,J=5.3,2.1Hz,1H),8.02–7.95(m,2H),7.48(dd,J=8.4,6.6Hz,2 H),7.42(d,J=1.4Hz,1H),7.36(dd,J=8.6,2.2Hz,1H),7.27(d,J=8.1Hz,1H),7.23(s,1H),7.10(s,1H),7.05(dd,J=8.1,1. 5Hz,1H),7.01–6.97(m,1H),6.95(d,J=2.4Hz,1H),6.89(t,J=7.5Hz,1H),4.40(td,J=7.9,5.8Hz,1H),4.08–3.97(m,2H),3 .91(d,J=7.0Hz,1H),3.43–3.33(m,2H),2.97(dd,J=14.5,5.8Hz,1H),2.87(dd,J=14.5,8.1Hz,1H),1.40(d,J=7.0Hz,3H). 13 CNMR (151MHz, DMSO-d 6 )δ173.47,172.06,140.55,140.51,138.34,135.96,127.18,125.36,124.92,123.70,123.49,122.73,120.81,120.52,120 .27,120.14,119.57,118.90,118.38,118.17,112.34,111.25,109.87,109.64,53.91,46.22,45.02,39.60,27.73,18.63.C 31 H 29 C1N 6 O 2 ,HRMS:m / z 553.2109[M+H] + (Calcd.553.2113).

[0092] Example 16

[0093] Activity evaluation of compounds 1-15:

[0094] The protective effect of compound 1-15 on cisplatin-induced mouse renal tubular epithelial cell (mRTEC) inflammation was evaluated by cell survival rate experiment (CCK-8 method), and the specific steps are as follows:

[0095] (1) mRTEC cells were cultured with F12 medium (10% FBS), digested, centrifuged, and counted, and 100 μL of 5000 cells / well were inoculated in the middle 60 wells of a 96-well plate, and PBS buffer was added to all the 34 wells at the edge, and cultured at 37°C for 24 h. The cell growth state and density were observed under a microscope, and wells with good growth state, uniform cell distribution and density were selected for the experiment.

[0096] (2) Each 96-well plate was divided into a normal group (NC), a model group (Cis), and an experimental group (Cis+Compounds), with six replicate wells in each group. The normal group was given physiological saline, the model group was added with 20 μM cisplatin, and the experimental group was first added with different concentrations (0.5 μM, 1 μM, 2 μM, 4 μM, 8 μM, 16 μM, 32 μM, 64 μM) of the target compound and cultured at 37°C for 12 h. Then, 20 μM cisplatin was added to each concentration of the experimental group and cultured for another 24 h.

[0097] (3) After 24 h of cisplatin stimulation, 10 μL of CCK-8 solution was added to each well and cultured for another 2 h at 37°C. The absorbance (OD value) was measured at 450 nm using a microplate reader. The experiment was repeated three times and the average value was taken. The maximum cell survival rate was calculated. The results are shown in Table 1.

[0098] Table 1

[0099]

[0100]

[0101] from Fig.10 It can be seen that the maximum cell survival rate of the positive control compound RH-1402 was higher when the administration concentration was 1 μM, 2 μM, and 4 μM, which were 72.6±9.2%, 73.9±3.7%, and 70.0±4.0%, respectively.

[0102] As shown in Table 1, compounds 12 and 13 have good anti-inflammatory effects. The maximum cell survival rate of compound 13 at a concentration of 4 μM reached 80.5±3.9%, which is higher than that of compound RH-1402; the maximum cell survival rate of compound 12 at a concentration of 0.5 μM was 73.0±3.3%. Although its protective effect on mRTEC cells was lower than that of compound 13, the concentration of the drug was lower. Compounds 1, 4, 5 and 11 showed good protective effects on mRTEC cells, with maximum cell survival rates between 65% and 70%.

[0103] Embodiment 17

[0104] Real-time PCR was used to detect the mRNA expression levels of related inflammatory factors:

[0105] mRTEC cells were cultured in 96-well plates and then divided into normal group (NC), experimental group 1 (Compounds: RH-1402, 12, 13), model group (Cis) and experimental group 2 (Cis+Compounds), with six replicates in each group. Normal saline was added to the normal group, 20 μM cisplatin was added to the model group, compounds with the maximum cell survival rate concentration were added to experimental group 1, and 20 μM cisplatin and compounds with the maximum cell survival rate concentration were added to experimental group 2. The culture was continued for 24 hours. mRTEC cells were collected, RNA was extracted with Trizol reagent, and the RNA of the sample was reverse transcribed into cDNA according to the instructions of the reverse transcription kit. The amplification reaction solution was prepared according to the instructions of the PCR amplification kit, and the reaction solution was added to the Real-time PCR amplification instrument for detection. The amplification conditions were: 95℃ denaturation for 20s, 58℃ annealing for 20s, and 72℃ extension for 20s, for 40 cycles. The relative expression of the target gene in each sample was calculated according to the Ct value (Cycle threshold) of the PCR fluorescence signal intensity, and the experimental data were processed with Excel and plotted with Graphpad Prism.

[0106] from Fig.11 It can be seen that the inhibitory effect of compound 12 on inflammatory factors TNF-α and MCP-1 is significantly stronger than that of the control compound RH-1402, and its dosage is significantly lower than that of the control compound RH-1402; the inhibitory effect of compound 13 on inflammatory factors TNF-α and MCP-1 is equivalent to that of the control compound RH-1402.

[0107] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. A 2-arylpropionic acid-L-tryptophan compound, characterized in that: The structural formula of the 2-arylpropionic acid-L-tryptophan compound is as follows: Wherein, Ar includes one of phenyl, substituted phenyl, naphthyl, substituted naphthyl, substituted biphenyl, and substituted carbazole.

2. The method for preparing the 2-arylpropionic acid-L-tryptophan compound according to claim 1, characterized in that: The preparation method comprises the following steps: (1) 2-Arylpropionic acid and L-tryptophan methyl ester hydrochloride undergo amide condensation reaction to obtain intermediate A; (2) Intermediate A undergoes hydrolysis to obtain intermediate B; (3) The intermediate B undergoes an amide condensation reaction with N-aminoethylimidazole hydrochloride to obtain the target compound. The synthetic route is as follows:

3. The preparation method according to claim 2, characterized in that: The amide condensation reaction is carried out in the presence of an acid binding agent, a condensing agent and an activating agent.

4. The preparation method according to claim 3, characterized in that: The acid binding agent is selected from at least one of triethylamine, pyridine, DIPEA, sodium carbonate and potassium carbonate.

5. The preparation method according to claim 3, characterized in that: The condensing agent is selected from at least one of DCC, EDCl, CDI, HATU, HBTU and T3P.

6. The preparation method according to claim 3, characterized in that: The activator is selected from at least one of HOBt, DMAP, 4-PPY and HOSu.

7. The preparation method according to claim 2, characterized in that: The hydrolysis reaction is carried out under alkaline conditions, and the alkaline conditions are provided by at least one of sodium carbonate, potassium carbonate, sodium hydroxide and potassium hydroxide.

8. Use of the 2-arylpropionic acid-L-tryptophan compound according to claim 1 or the 2-arylpropionic acid-L-tryptophan compound prepared by the preparation method according to any one of claims 2 to 7 in the preparation of a GRPR small molecule inhibitor.

9. Use of the 2-arylpropionic acid-L-tryptophan compound according to claim 1 or the 2-arylpropionic acid-L-tryptophan compound prepared by the preparation method according to any one of claims 2 to 7 in the preparation of a drug for preventing and / or treating a disease associated with abnormal expression of GRPR activity.

10. The use according to claim 9, characterized in that: The diseases associated with abnormal expression of GRPR activity include inflammation, neurodegenerative diseases, renal fibrosis, autoimmune diseases, etc.

Citation Information

Patent Citations

  • Compound having anti-itching activity

    CN101786990A

  • Compound with anticancer activity and preparation method thereof

    CN102603619A

  • Peptidomimetic compound with anti-inflammation activity as well as preparation method and pharmaceutical application thereof

    CN108440504A